Rezolute Inc
RZLT5.805USD
-0.065-1.11%
交易中 （美東）報價延遲15分鐘
351.45M總市值
虧損本益比TTM
關於 Rezolute Inc 公司
Rezolute, Inc. 是一家後期罕見病公司，專注於改善因高胰島素血癥 (HI) 引起的低血糖症患者的治療效果。其主要臨牀資產 Ersodetug（原名 RZ358）是一種潛在的治療由多種形式的高胰島素血癥引起的低血糖症的方法，包括先天性 HI 和腫瘤性 HI。Ersodetug 是一種靜脈注射的人類單克隆抗體，可與胰島素靶組織（例如肝臟、脂肪和肌肉）中胰島素受體上的獨特位點（變構）結合。先天性是一種罕見的兒科遺傳性疾病，其特徵是胰腺過量產生胰島素。RZ402 是一種口服血漿激肽釋放酶抑制劑 (PKI)，正在開發作爲糖尿病性黃斑水腫 (DME) 慢性治療的潛在療法。DME 是糖尿病的血管併發症，也是失明的主要原因。RZ402 旨在阻止緩激肽的產生及其對血管滲漏和炎症的影響。
公司簡介
公司代碼RZLT
公司名稱Rezolute Inc
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
員工數量59
證券類型Ordinary Share
年結日Dec 23
公司地址275 Shoreline Drive, Suite 500
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94065
電話16502064507
網址https://www.rezolutebio.com/
公司代碼RZLT
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
149.95K
+6.39%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
93.03K
+10.71%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
37.58K
+47.36%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
34.50K
+35.29%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
Mr. Daron Evans
Mr. Daron Evans
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Independent Director
Independent Director
--
--
Dr. Brian K. Roberts, M.D.
Dr. Brian K. Roberts, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Erik Harris
Mr. Erik Harris
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
149.95K
+6.39%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
93.03K
+10.71%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
37.58K
+47.36%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
34.50K
+35.29%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
Mr. Daron Evans
Mr. Daron Evans
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
12.99%
Handok Inc
8.29%
Fidelity Management & Research Company LLC
7.24%
The Vanguard Group, Inc.
2.74%
Vivo Capital, LLC
2.43%
Other
66.31%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
12.99%
Handok Inc
8.29%
Fidelity Management & Research Company LLC
7.24%
The Vanguard Group, Inc.
2.74%
Vivo Capital, LLC
2.43%
Other
66.31%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
20.30%
Hedge Fund
14.64%
Investment Advisor
13.13%
Corporation
8.29%
Venture Capital
2.47%
Individual Investor
1.41%
Research Firm
1.34%
Pension Fund
0.16%
Private Equity
0.05%
Other
38.21%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
151
53.63M
61.77%
-9.40M
2025Q1
149
54.85M
64.71%
-11.78M
2024Q4
130
52.42M
86.65%
+2.62M
2024Q3
103
45.09M
85.49%
-8.77M
2024Q2
88
47.89M
96.58%
+4.94M
2024Q1
69
35.39M
87.04%
-8.22M
2023Q4
65
37.08M
93.56%
-2.65M
2023Q3
67
32.22M
86.09%
-5.29M
2023Q2
66
32.97M
88.12%
-2.31M
2023Q1
64
32.97M
87.27%
-2.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
11.28M
12.99%
--
--
Mar 31, 2025
Handok Inc
7.19M
8.29%
+1.25M
+21.03%
Oct 07, 2024
Fidelity Management & Research Company LLC
6.29M
7.24%
-72.11K
-1.13%
Mar 31, 2025
The Vanguard Group, Inc.
2.38M
2.74%
+54.37K
+2.34%
Mar 31, 2025
Vivo Capital, LLC
2.11M
2.43%
-685.27K
-24.49%
Mar 31, 2025
Marshall Wace LLP
1.85M
2.13%
+1.00M
+118.85%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.74M
2.01%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
1.70M
1.96%
+125.00K
+7.94%
Mar 31, 2025
Caxton Associates LP
1.32M
1.52%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.29M
1.49%
-1.57M
-54.81%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.26%
iShares Micro-Cap ETF
0.07%
iShares Russell 2000 Growth ETF
0.02%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Value ETF
0%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.26%
iShares Micro-Cap ETF
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.01%
iShares Russell 2000 Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
